• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine

Mary Wilson

Well-known member
This is a PDF file of a peer-reviewed paper that has been accepted for publication.
Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and gures will undergo copyediting and a proof review before the paper is published in its nal form. Please note that during the production process errors may be discovered which could a ect the content, and all legal disclaimers apply.


Published online 28 July 2021

doi.org/10.1038/s41586-021-03841-4 (2021).

Valerie Oberhardt1,2,12, Hendrik Luxenburger1,3,12, Janine Kemming1,2,12, Isabel Schulien1,12, Kevin Ciminski4, Sebastian Giese4, Benedikt Csernalabics1, Julia Lang-Meli1,3, Iga Janowska5, Julian Staniek2,5, Katharina Wild1,6, Kristi Basho1, Mircea Stefan Marinescu1, Jonas Fuchs4, Fernando Topfstedt5, Ales Janda7, Oezlem Sogukpinar1, Hanna Hilger1, Katarina Stete1, Florian Emmerich8, Bertram Bengsch1,9, Cornelius F. Waller10, Siegbert Rieg1, Sagar1,
Tobias Boettler1,11, Katharina Zoldan1, Georg Kochs4, Martin Schwemmle4, Marta Rizzi5, Robert Thimme1,13✉, Christoph Neumann-Haefelin1,13✉ & Maike Hofmann1,13


Abstract

SARS-CoV-2 spike mRNA vaccines[SUP]1–3[/SUP] mediate protection from severe disease as early as 10 days post prime vaccination[SUP]3[/SUP], when neutralizing antibodies are hardly detectable[SUP]4–6[/SUP]. Vaccine-induced CD8+ T cells may thus be the main mediators of protection at this early stage[SUP]7,8[/SUP]. The details of their induction, comparison to natural infection, and association with other arms of vaccine-induced immunity remain, however, incompletely understood. We show on a single epitope level that a stable and fully functional CD8+ T cell response is vigorously mobilized one week after bnt162b2 prime vaccination when circulating CD4+ T cells and neutralizing antibodies are still weakly detectable. Boost vaccination induced a robust expansion generating highly differentiated effector CD8+ T cells; however, neither the functional capacity nor the memory precursor T cell pool was affected. Compared to natural infection, vaccine-induced early memory T cells exhibited similar functional capacities but a different subset distribution. Our results indicate that CD8+ T cells are important effector cells, expanded in the early protection window after prime vaccination, precede maturation of other effector arms of vaccine-induced immunity and are stably maintained after boost vaccination.

https://www.nature.com/articles/s41586-021-03841-4_reference.pdf
 
Back
Top Bottom